Cargando…
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd on behalf of European Society for Medical Oncology.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326208/ https://www.ncbi.nlm.nih.gov/pubmed/34352377 http://dx.doi.org/10.1016/j.annonc.2021.07.015 |
| _version_ | 1783731732849098752 |
|---|---|
| author | Pommeret, F. Colomba, J. Bigenwald, C. Laparra, A. Bockel, S. Bayle, A. Michot, J.-M. Hueso, T. Albiges, L. Tiberghien, P. Marot, S. Jary, A. Lacombe, K. Barlesi, F. Griscelli, F. Colomba, E. |
| author_facet | Pommeret, F. Colomba, J. Bigenwald, C. Laparra, A. Bockel, S. Bayle, A. Michot, J.-M. Hueso, T. Albiges, L. Tiberghien, P. Marot, S. Jary, A. Lacombe, K. Barlesi, F. Griscelli, F. Colomba, E. |
| author_sort | Pommeret, F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8326208 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier Ltd on behalf of European Society for Medical Oncology. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83262082021-08-02 Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies Pommeret, F. Colomba, J. Bigenwald, C. Laparra, A. Bockel, S. Bayle, A. Michot, J.-M. Hueso, T. Albiges, L. Tiberghien, P. Marot, S. Jary, A. Lacombe, K. Barlesi, F. Griscelli, F. Colomba, E. Ann Oncol Letter to the Editor Published by Elsevier Ltd on behalf of European Society for Medical Oncology. 2021-11 2021-08-02 /pmc/articles/PMC8326208/ /pubmed/34352377 http://dx.doi.org/10.1016/j.annonc.2021.07.015 Text en © 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Pommeret, F. Colomba, J. Bigenwald, C. Laparra, A. Bockel, S. Bayle, A. Michot, J.-M. Hueso, T. Albiges, L. Tiberghien, P. Marot, S. Jary, A. Lacombe, K. Barlesi, F. Griscelli, F. Colomba, E. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title | Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title_full | Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title_fullStr | Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title_full_unstemmed | Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title_short | Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies |
| title_sort | bamlanivimab + etesevimab therapy induces sars-cov-2 immune escape mutations and secondary clinical deterioration in covid-19 patients with b-cell malignancies |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326208/ https://www.ncbi.nlm.nih.gov/pubmed/34352377 http://dx.doi.org/10.1016/j.annonc.2021.07.015 |
| work_keys_str_mv | AT pommeretf bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT colombaj bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT bigenwaldc bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT laparraa bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT bockels bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT baylea bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT michotjm bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT huesot bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT albigesl bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT tiberghienp bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT marots bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT jarya bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT lacombek bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT barlesif bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT griscellif bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies AT colombae bamlanivimabetesevimabtherapyinducessarscov2immuneescapemutationsandsecondaryclinicaldeteriorationincovid19patientswithbcellmalignancies |